‘New Mechanism’ Could Join Lilly Diabetes Fight
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe global development leader of Lilly Diabetes says a new $55 million agreement could open the door for potentially innovative treatments for patients with type 2 diabetes and other metabolic conditions. Brad Woodward says the collaboration with Switzerland-based KeyBioscience AG taps into "an entirely new mechanism" to potentially improve control of blood glucose and weight loss. The value of the commercialization and development deal could rise if milestones are met and treatments reach the marketplace.
Woodward tells Inside INdiana Business the partnership involves multiple molecules at various stages of development. One, called KBP-042, is in phase two of development and those results could be in by the middle of next year. Woodward says the other molecules are in stages ranging from phase one to pre-clinical.
The agreement, which still must clear standard regulatory hurdles, involves worldwide development and commercialization rights for Lilly. You can read more about the collaboration by clicking here.
Woodward tells Inside INdiana Business the partnership involves multiple molecules at various stages of development.